
Opinion|Videos|January 20, 2025
Care Coordination and Transition Strategies for CAR-T Therapy
Panelists discuss their institution’s approach to co-management and co-monitoring of (chimeric antigen receptor (CAR) -T patients, strategies to facilitate seamless transitions of care between academic centers and community practices, common challenges in the CAR -T referral process and solutions, and advice for community physicians on the timing and preparation for patient referrals.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Describe your institution’s approach to the co-management and co-monitoring of patients receiving CAR-T therapy, particularly in the transition back to the community setting.
- Can you share any specific strategies or tools your institution utilizes to facilitate seamless transitions of care between the academic center and community practices for CAR-T patients?
- What are the most common challenges you have encountered in the CAR-T referral process, and how have you addressed them at your institution?
- What advice would you provide to community physicians regarding the appropriate timing and preparation for referring patients for CAR-T therapy?
Advertisement
Related to this article

In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.

“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.

Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Setting Up an HDR Brachytherapy Program Amid a National Decline
2
Biomarker Sequencing, PD-L1 Status, and FLOT Dosing in Gastroesophageal Cancer
3
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
4
CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma
5

